IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Acadia expects Rett drug protection through 2041 — 9hAcadia Pharmaceuticals received a U.S. patent allowance covering weight-banded dosing of trofinetide, the active ingredient in DAYBUE and DAYBUE STIX for Rett syndrome. Including pediatric exclusivity, the patent is expected to extend U.S. protection to March 28, 2041—nearly five years beyond existing method-of-use protection.

Maya Lindstrom Five more years of exclusivity on DAYBUE might limit access for patients who need weight-based dosing options.